Lipigon Pharmaceuticals (Lipigon) announced that it has entered into a development and licensing agreement with Leaderna Therapeutics Ltd. (Leaderna) regarding Lipisense®? in Greater China. Leaderna will be responsible for the development and commercialization of Lipisense®?

in mainland China, Hong Kong, Taiwan, and Macau (collectively known as Greater China). Lipigon will retain the global development and commercial rights outside of Greater China. As part of the agreement, Lipigon will receive an upfront payment and may receive milestone payments plus royalties on sales in Greater China up to a total of USD 91 million.